NEW YORK, March 24, 2020 /PRNewswire/ -- Renalytix AI
plc (LSE: RENX), the AIM-traded developer of clinical
grade artificial intelligence in vitro diagnostics
for kidney disease, announces that data from a study
highlighting the health economic benefits associated with
KidneyIntelX™ testing in diabetic kidney disease
populations (DKD) will be presented at the National Kidney
Foundation Spring Clinical Meeting. An abstract summarizing key
results will be published in the peer reviewed journal, the
American Journal of Kidney Disease.
National Kidney Foundation Spring Clinical Meeting
(March 26, 2020)
Thomas Goss, PharmD, Senior Vice President,
Boston Healthcare Associates, will deliver a presentation
titled Evaluation of Payer Budget Impact Associated with the
Use of Artificial Intelligence in vitro Diagnostic, KidneyIntelX™,
to Modify DKD Progression during the Late Breaking
Abstract session at the National Kidney Foundation's Spring
Clinical Meeting. The presentation will highlight the
significant cost savings associated with the implementation of
KidneyIntelX™ in large health care system patient
populations in the United
States. The presentation is based on a comprehensive
economic model developed by Boston Healthcare Associates utilizing
peer reviewed clinical data to estimate the costs associated with
chronic kidney disease progression in the U.S. The presentation
session will be held on Thursday, March 26,
2020 at 4:15 PM ET. A summary
of the presentation results will be made available on the Company's
website.
"The results suggest substantial cost savings can be achieved
using KidneyIntelX™ to assess CKD patient
populations at risk of rapid kidney function decline and/or kidney
failure under a number of different scenarios
tested," said Thomas Goss,
Senior Vice President at Boston Healthcare Associates Inc.
An abstract summarizing the results will also be published in
the May 2020 issue of the
American Journal of Kidney Disease (www.ajkd.org),
the official journal of the National Kidney Foundation,
which is recognized worldwide as a leading source of
information devoted to clinical nephrology practice and clinical
research.
NKF's Spring Clinical Meeting gathers more than 3,000
nephrology healthcare professionals from across the United States to learn about the newest
developments related to all aspects of nephrology
practice. Due to the coronavirus and coronavirus disease
(COVID-19) outbreak in the United
States the meeting is being held as a live virtual event in
2020. Sessions can be accessed through the conference website.
About Kidney Disease
Kidney disease is now
recognized as a public health epidemic affecting over 850 million
people globally. The Centers for Disease Control and
Prevention (CDC) estimates that 15% of US adults, or 37 million
people, currently have chronic kidney disease (CKD). Further,
the CDC reports that 9 out of 10 adults with CKD do not know they
have it and 1 out of 2 people with very low kidney function who are
not on dialysis do not know they have CKD*. Kidney disease is
referred to as a "silent killer" because it often has no symptoms
and can go undetected until a very advanced stage. Each year
kidney disease kills more people than breast and prostate
cancer. Every day, 13 patients in the United States die while waiting for a
kidney transplant.
About RenalytixAI
RenalytixAI is a developer of
clinical grade, artificial intelligence-enabled in
vitro diagnostic solutions for kidney disease, one of the
most common and costly chronic medical conditions globally. The
Company's products are being designed to make significant
improvements in kidney disease diagnosis, transplant management,
clinical care, and patient stratification for drug clinical trials.
For more information, visit renalytixai.com.
* https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html
View original
content:http://www.prnewswire.com/news-releases/renalytixai-announces-podium-presentation-and-publication-on-evaluation-of-payer-budget-impact-associated-with-the-use-of-artificial-intelligence-in-vitro-diagnostic-kidneyintelx-to-modify-dkd-progression-301028758.html
SOURCE RenalytixAI